Company type
Limited Corporation
Established
1999
Size
Medium
Employees
227
Revenue
580 MDKK
Gross profit
144 MDKK
Operating Profit (EBIT)
119 MDKK
Profit for the Year
371 MDKK
Equity
404 MDKK
ad

More financial key figures and analyses?

In Bisbase Premium you get more financial key figures for both companies, groups and industries plus access to exclusive industries complied by experts. You can also create your own analyses! It only takes a minute or so - and it's free!

Rank Profit for the Year

Rank in industry
1/363
"Top 10%"
Rank in Denmark
361/303,195
"Top 10%"

Top management Top 3

Board Top 3

Stephan Selke 2Chairman of board
John Ditlev Larsen 2Boardmember
George Lloyd Miller 2Boardmember

Legal owners Top 3

100%West Pharmaceutical Services Holding Danmark Aps

Rights certificate

Selskabet tegnes af to medlemmer af bestyrelsen i forening eller af bestyrelsens formand i forening med en direktør

Company information based on CVR

NameWest Pharmaceutical Services Danmark A/S
Alternate namesPharmaceutical Rubber Co. A/S, Schiønning & Arve A/S, Schubert Seals A/S, The West Company, Danmark A/S, West Pharmaceutical Services Finance Danmark A/S Show more
CVR16210714
AddressFuglevangsvej 51, 8700 Horsens
IndustryManufacture of light metal packaging [259200]
Webhttp://
Established16-10-1999 (21 yr)
Company typeLimited Corporation
Number of employees227 (Fin.Stmt)
Advertising protectionNo
AuditorPricewaterhousecoopers Statsautoriseret Revisionspartnerselskab since 01-07-2011
Financial statement period01-01 to 31-12
Bank connectionDanske Bank
Company capital50,000,000 DKK
25,000,000 DKK (10-11-1994 - 16-12-1999)
20,000,000 DKK (04-03-1991 - 09-11-1994)
9,500,000 DKK (30-08-1987 - 03-03-1991)
Articles of assoc. last19-05-2010

Member of industries

Purpose

Selskabets formål er at drive handel og produktion og anden i forbindelse hermed stående virksomhed

Financial Statement

 201820172016
Currency/unit000' DKK000' DKK000' DKK
Revenue
579,734
+11%
521,704
+0%
519,693
-1%
Gross Profit
144,467
+13%
127,463
-11%
142,905
-6%
Profit for the Year
371,198
-1%
375,664
+6%
354,406
+38%
Equity
404,037
-80%
2,052,591
-1%
2,079,505
+21%
Total Assets
1,116,503
-60%
2,764,508
+16%
2,387,767
+16%

Mangement review

LedelsesberetningHovedaktivitetSelskabet producerer og afsætter farmaceutisk gummi og metal emballage komponenter globalt.Udvikling i regnskabsåretDet samlede resultat for 2018 på DKK 371,2 mio. er som forventet og anses for tilfredsstillende.Selskabets omsætning er steget til DKK 579,7 mio. fra 521,7 mio. svarende til en stigning på 11,1%, og resultat før finansielle poster er steget til DKK 72,5 mio. fra DKK 54,6 mio.Indtjeningen i selskabets udenlandske datterselskaber udviser et resultat efter skat og goodwill afskrivninger på DKK 323,6 mio. mod et overskud sidste år på DKK 331,7 mio.Finansielle nettoudgifter udgør DKK 11,5 mio. mod nettoindtægter på DKK 1,8 mio. sidste år.Skat af årets resultat, eksklusive skatter i datterselskaber, udgør DKK 13,5 mio. mod DKK 12,4 mio. sidste år.I 2018 blev det besluttet at udlodde ekstraordinært udbytte på i alt DKK 1,973 mio.Særlige risiciSelskabet har ingen driftsrisici eller finansielle risici ud over de almindeligt forekommende risici inden for selskabets branche.Usikkerhed ved indregning og målingDer er ikke forekommet usikkerhed ved indregning og måling i årsrapportenUsædvanlige forholdSelskabets aktiver, passiver og finansielle stilling pr. 31. december 2018 samt resultatet af selskabets aktiviteter og pengestrømme for 2018 er ikke påvirket af usædvanlige forhold.Strategi og målsætningerStrategiSelskabets strategi er at være en kundeorienteret pharmaceutisk fabrik, der leverer produkter med den rigtige kvalitet, og producerer under og overholder gældende cGMP regler.Selskabet vil etablere partnerskab med vores nøglekunder ved at være pålidelige, troværdige og fokuseret på vores processer og kundernes behov, så selskabet vil imødekomme deres forventninger samtidig med at selskabets økonomiske resultat fastholdesMålsætninger og forventninger for det kommende årFor 2019 forventes aktivitetsniveauet og resultatet af den primære drift at være lavere end 2018, hvilket skyldes en omskiftning i produktmiks.Investeringer vil være afpasset med fremtidige behov for kapacitet og teknologisk udvikling.Selskabet forventer at fastholde investeringsniveauet i 2019 pga. investering i nyt udstyr og den løbende modernisering af fabrikken.Investeringerne forventes finansieret via pengestrømme fra driften, hvorfor den likvide beholdning ultimo 2019 forventes at være på niveau med 2018.Grundlaget for indtjeningenVort grundlag for indtjening er produktionen af primære pakkematerialer for den farmaceutiske marked kombineret med vort kvalitetssikringssystem som skal udvikles i takt med markedskravene.Eksternt miljøSelskabet prioriterer miljøet højt og har derfor i organisationen en dedikeret ressource til HSE (Health, Safety and Environment). Det er Selskabets målsætning, som et minimum at overholde alle miljømæssige krav så en forsvarlig driftsførelse kan opretholdes., Management’s ReviewMain activityThe company is producing and selling pharmaceutical rubber and metal packaging components worldwide.Development in the yearThe total result of 2018 on DKK 371,2 mill. is as expected and is considered satisfactory.The turnover of the company has increased to DKK 579,7 mill. from DKK 521,7 mill. which correspond to an increase of 11,1 %, and the result before financial entries has increased to DKK 72,5 mill. from DKK 54,6 mill.The earnings of the subsidiaries of the company shows a result after tax and depreciation on goodwill of DKK 323,6 mill against a result last year of DKK 331,7 mill.Financial net expense amount to DKK 11,5 mill against net income amount DKK 1,8 mill last year.The tax on the result of the year, exclusive tax of subsidiaries, amount to DKK 13,5 mill against DKK 12,4 mill last year.In 2018 it was decided to distribute non annual dividends, totalling DKK 1.973 mio.Special risksThe company do not have any operational or financial risks beside the common risks within the line of the company.Uncertainty on adding in and measurementNo uncertainty on adding in and measurement for the annual report has occurred.Extraordinary circumstancesThe financial position at 31 December 2018 of the Company and the results of the activities and cash flows of the Company for the financial year for 2018 have not been affected by any unusual events.Strategy and targetsStrategyIt is the company strategy to be a customer focused pharmaceutical plant, and to deliver products with the right quality, produced under cGMP conditions.The company will establish partnership with our key customers being reliable, accountable and focused on our processes and customer needs, so the company will meet and exceed their expectations, and on the same time maintain the company result.Targets and expectations for the following yearThe level of activity and result in 2019 is expected to be below the level in 2018 due to changes in the productmix.Investments will adapt to future need for capacity and technologically development.The company expect to maintain the level of investment in 2019 due to investment in new equipment and the ongoing modernization of the plant.The investments are expected to be financed through the cash flow from the operation, why the available funds year end 2019 is expected to be at the same level as at year 2018.The basis for the earningsThe basis for the earnings is our production of primary packaging materials for the pharmaceutical market combined with our quality system which therefore will be developed in time with the demands on the market.External environmentThe environment is a high priority for the Company and the company has therefore in the organization a dedicated resource for HSE (health, Safety and Environment). It is the goal for the Company as a minimum, to meet all environmental requirement so a responsible operation can be maintained.
29-05-2019

Map